Showing results (371-380 of 395) with videos related to

Sort By:
Pageof 40
Open Forum Infectious Diseases|November 18, 2020
Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19Sarah M Lofgren, Melanie R Nicol, Ananta S Bangdiwala, et al.
Journal of the International AIDS Society|June 6, 2025
Household economic impact of HIV-associated cryptococcal meningitis in five countries in Southern and Eastern AfricaDavid S Lawrence, Charles Muthoga, Jack Adams, et al.
The Lancet. Infectious Diseases|August 21, 2025
A clinical practice guideline for tuberculous meningitisJoseph Donovan, Fiona V Cresswell, Elizabeth W Tucker, et al.
The Lancet. Global Health|November 18, 2022
Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trialDavid S Lawrence, Charles Muthoga, David B Meya, et al.
The New England Journal of Medicine|March 30, 2022
Effect of Early Treatment with Ivermectin among Patients with Covid-19Gilmar Reis, Eduardo A S M Silva, Daniela C M Silva, et al.
JAMA|November 17, 2023
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical TrialThomas G Stewart, Paulina A Rebolledo, Ahmad Mourad, et al.
Medrxiv : the Preprint Server for Health Sciences|May 27, 2024
Effect of Montelukast vs Placebo on Time to Sustained Recovery in Outpatients with COVID-19: The ACTIV-6 Randomized Clinical TrialRussell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
The Lancet. Infectious Diseases|September 29, 2024
Advancing the chemotherapy of tuberculous meningitis: a consensus viewSean Wasserman, Joseph Donovan, Evelyne Kestelyn, et al.
JAMA Network Open|October 18, 2024
Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo: The ACTIV-6 Randomized Clinical TrialRussell L Rothman, Thomas G Stewart, Ahmad Mourad, et al.
BMJ Open|April 4, 2019
AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence studyPonego Lloyd Ponatshego, David Stephen Lawrence, Nabila Youssouf, et al.
Pageof 40